| Dr Jessica Anne Mcpherson, MD | |
|
101 Manning Dr, Chapel Hill, NC 27514-4220 | |
| (919) 966-1601 | |
| Not Available |
| Full Name | Dr Jessica Anne Mcpherson |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 15 Years |
| Location | 101 Manning Dr, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538397112 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2009012952 (Missouri) | Secondary |
| 207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | 2013-00296 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wake Forest University Health Sciences | 4486564952 | 1987 |
News Archive
A study of Catholic obstetrician-gynecologists shows that many face moral dilemmas when dealing with issues of family planning and abortion due to their religious faith, according researchers at the University of Colorado Anschutz Medical Campus.
Neuroscientists from Tübingen have discovered how our brain processes visual stimuli above and below the horizon differently.
Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.
The American College of Sports Medicine, with support from the Anthem Blue Cross and Blue Shield Foundation, is expanding the ACSM American Fitness Index Technical Assistance Program to Cincinnati. Working with the Cincinnati Health Department's Creating Healthy Communities Coalition, ACSM unveiled a comprehensive strategic plan today that will guide the Cincinnati metro area toward improved health and fitness outcomes.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 6 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
A study of Catholic obstetrician-gynecologists shows that many face moral dilemmas when dealing with issues of family planning and abortion due to their religious faith, according researchers at the University of Colorado Anschutz Medical Campus.
Neuroscientists from Tübingen have discovered how our brain processes visual stimuli above and below the horizon differently.
Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.
The American College of Sports Medicine, with support from the Anthem Blue Cross and Blue Shield Foundation, is expanding the ACSM American Fitness Index Technical Assistance Program to Cincinnati. Working with the Cincinnati Health Department's Creating Healthy Communities Coalition, ACSM unveiled a comprehensive strategic plan today that will guide the Cincinnati metro area toward improved health and fitness outcomes.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 6 days ago
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
A study of Catholic obstetrician-gynecologists shows that many face moral dilemmas when dealing with issues of family planning and abortion due to their religious faith, according researchers at the University of Colorado Anschutz Medical Campus.
Neuroscientists from Tübingen have discovered how our brain processes visual stimuli above and below the horizon differently.
Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.
The American College of Sports Medicine, with support from the Anthem Blue Cross and Blue Shield Foundation, is expanding the ACSM American Fitness Index Technical Assistance Program to Cincinnati. Working with the Cincinnati Health Department's Creating Healthy Communities Coalition, ACSM unveiled a comprehensive strategic plan today that will guide the Cincinnati metro area toward improved health and fitness outcomes.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 6 days ago
| Entity Name | Firsthealth Of The Carolinas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548276389 PECOS PAC ID: 8820909377 Enrollment ID: O20031108000016 |
News Archive
A study of Catholic obstetrician-gynecologists shows that many face moral dilemmas when dealing with issues of family planning and abortion due to their religious faith, according researchers at the University of Colorado Anschutz Medical Campus.
Neuroscientists from Tübingen have discovered how our brain processes visual stimuli above and below the horizon differently.
Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.
The American College of Sports Medicine, with support from the Anthem Blue Cross and Blue Shield Foundation, is expanding the ACSM American Fitness Index Technical Assistance Program to Cincinnati. Working with the Cincinnati Health Department's Creating Healthy Communities Coalition, ACSM unveiled a comprehensive strategic plan today that will guide the Cincinnati metro area toward improved health and fitness outcomes.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Anne Mcpherson, MD 518 Perkins Dr, Chapel Hill, NC 27514-1793 Ph: () - | Dr Jessica Anne Mcpherson, MD 101 Manning Dr, Chapel Hill, NC 27514-4220 Ph: (919) 966-1601 |
News Archive
A study of Catholic obstetrician-gynecologists shows that many face moral dilemmas when dealing with issues of family planning and abortion due to their religious faith, according researchers at the University of Colorado Anschutz Medical Campus.
Neuroscientists from Tübingen have discovered how our brain processes visual stimuli above and below the horizon differently.
Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.
The American College of Sports Medicine, with support from the Anthem Blue Cross and Blue Shield Foundation, is expanding the ACSM American Fitness Index Technical Assistance Program to Cincinnati. Working with the Cincinnati Health Department's Creating Healthy Communities Coalition, ACSM unveiled a comprehensive strategic plan today that will guide the Cincinnati metro area toward improved health and fitness outcomes.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 6 days ago
George Nowacek, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-843-7851 Fax: 540-368-5206 | |
Christine Mirng-en Chu, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 919-966-5283 | |
Dr. Mary Elizabeth Schlegel, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: University Of North Carolina Campus Health Service, Cb # 7470, Chapel Hill, NC 27599 Phone: 919-843-6301 Fax: 919-966-6356 | |
Dr. Stuart-allison Moffat Staley, MD, MPH Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Department Of Ob/gyn, Chapel Hill, NC 27514 Phone: 919-966-6823 Fax: 919-966-6356 | |
Lauren Nord Tholemeier, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Dr. Linda Van Le, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-4996 Fax: 919-843-5515 | |
Erica Lynn O'neill, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Unc Hospitals, Chapel Hill, NC 27514 Phone: 919-843-6301 Fax: 919-966-6356 |